Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuro psychiatric diseases?
Craig M Smith, Andrew W Walker, Ihaia T Hosken, Berenice E Chua, Cary Zhang, Mouna Haidar, Andrew L Gundlach
FRONTIERS IN PHARMACOLOGY | FRONTIERS MEDIA SA | Published : 2014
Related Projects (3)
Awarded by National Health and Medical Research Council (NHMRC) of Australia
The research in the authors' laboratory reviewed here was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (509246, 1005988, and 1024885) and the Pratt and Besen Foundations, and by the Victorian Government Strategic Investment. Andrew L. Gundlach is an NHMRC (Australia) Senior Research Fellow and a Brain & Behavior Research Foundation (USA) NARSAD Independent Investigator. The authors acknowledge the contribution of their current and former colleagues to the relaxin-3 related research reviewed.